Involvement of functional autoantibodies against vascular receptors in systemic sclerosis

Background Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological f...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 70; no. 3; pp. 530 - 536
Main Authors Riemekasten, Gabriela, Philippe, Aurélie, Näther, Melanie, Slowinski, Torsten, Müller, Dominik N, Heidecke, Harald, Matucci-Cerinic, Marco, Czirják, László, Lukitsch, Ivo, Becker, Mike, Kill, Angela, van Laar, Jacob M, Catar, Rusan, Luft, Friedrich C, Burmester, Gerd R, Hegner, Björn, Dragun, Duska
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and European League Against Rheumatism 01.03.2011
BMJ Publishing Group
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc. Methods Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT1R) and endothelin-1 type A receptor (ETAR) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality. Results Anti-AT1R and anti-ETAR autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists. Conclusions Functional autoimmunity directed at AT1R and ETAR is common in patients with SSc. AT1R and ETAR autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression.
AbstractList Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc. Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT(1)R) and endothelin-1 type A receptor (ET(A)R) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality. Anti-AT(1)R and anti-ET(A)R autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists. Functional autoimmunity directed at AT(1)R and ET(A)R is common in patients with SSc. AT(1)R and ET(A)R autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression.
Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc.BACKGROUNDSystemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc.Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT(1)R) and endothelin-1 type A receptor (ET(A)R) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality.METHODSSerum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT(1)R) and endothelin-1 type A receptor (ET(A)R) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality.Anti-AT(1)R and anti-ET(A)R autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists.RESULTSAnti-AT(1)R and anti-ET(A)R autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists.Functional autoimmunity directed at AT(1)R and ET(A)R is common in patients with SSc. AT(1)R and ET(A)R autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression.CONCLUSIONSFunctional autoimmunity directed at AT(1)R and ET(A)R is common in patients with SSc. AT(1)R and ET(A)R autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression.
Background Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc. Methods Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT1R) and endothelin-1 type A receptor (ETAR) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality. Results Anti-AT1R and anti-ETAR autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists. Conclusions Functional autoimmunity directed at AT1R and ETAR is common in patients with SSc. AT1R and ETAR autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression.
BACKGROUND: Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc. METHODS: Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT1R) and endothelin-1 type A receptor (ETAR) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality. RESULTS: Anti-AT1R and anti-ETAR autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor beta gene expression in endothelial cells which could be blocked with specific receptor antagonists. CONCLUSIONS: Functional autoimmunity directed at AT1R and ETAR is common in patients with SSc. AT1R and ETAR autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression.
Background Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in vasculopathy and fibrosis. A role for autoantibody-mediated receptor stimulation is hypothesised, linking three major pathophysiological features consistent with SSc. Methods Serum samples from 478 patients with SSc (298 in the study cohort and 180 from two further independent cohorts), 372 healthy subjects and 311 control-disease subjects were tested for antibodies against angiotensin II type 1 receptor (AT1 R) and endothelin-1 type A receptor (ETA R) by solid phase assay. Binding specificities were tested by immunoprecipitation. The biological effects of autoantibodies in microvascular endothelial cells in vitro were also determined, as well as the quantitative differences in autoantibody levels on specific organ involvements and their predictive value for SSc-related mortality. Results Anti-AT1 R and anti-ETA R autoantibodies were detected in most patients with SSc. Autoantibodies specifically bound to respective receptors on endothelial cells. Higher levels of both autoantibodies were associated with more severe disease manifestations and predicted SSc-related mortality. Both autoantibodies exert biological effects as they induced extracellular signal-regulated kinase 1/2 phosphorylation and increased transforming growth factor β gene expression in endothelial cells which could be blocked with specific receptor antagonists. Conclusions Functional autoimmunity directed at AT1 R and ETA R is common in patients with SSc. AT1 R and ETA R autoantibodies could contribute to disease pathogenesis and may serve as biomarkers for risk assessment of disease progression.
Author Becker, Mike
Luft, Friedrich C
Kill, Angela
Philippe, Aurélie
Catar, Rusan
Näther, Melanie
Hegner, Björn
Burmester, Gerd R
Lukitsch, Ivo
van Laar, Jacob M
Slowinski, Torsten
Riemekasten, Gabriela
Matucci-Cerinic, Marco
Müller, Dominik N
Czirják, László
Heidecke, Harald
Dragun, Duska
Author_xml – sequence: 1
  givenname: Gabriela
  surname: Riemekasten
  fullname: Riemekasten, Gabriela
  email: duska.dragun@charite.de
  organization: Department of Rheumatology, German Rheumatology Research Center, Leibniz Institute, Berlin, Germany
– sequence: 2
  givenname: Aurélie
  surname: Philippe
  fullname: Philippe, Aurélie
  email: duska.dragun@charite.de
  organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany
– sequence: 3
  givenname: Melanie
  surname: Näther
  fullname: Näther, Melanie
  email: duska.dragun@charite.de
  organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany
– sequence: 4
  givenname: Torsten
  surname: Slowinski
  fullname: Slowinski, Torsten
  email: duska.dragun@charite.de
  organization: Department of Nephrology, CCM, Charité University Hospital, Berlin, Germany
– sequence: 5
  givenname: Dominik N
  surname: Müller
  fullname: Müller, Dominik N
  email: duska.dragun@charite.de
  organization: Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine, Berlin, Germany
– sequence: 6
  givenname: Harald
  surname: Heidecke
  fullname: Heidecke, Harald
  email: duska.dragun@charite.de
  organization: CellTrend GmbH Luckenwalde, Luckenwalde, Germany
– sequence: 7
  givenname: Marco
  surname: Matucci-Cerinic
  fullname: Matucci-Cerinic, Marco
  email: duska.dragun@charite.de
  organization: Department of Rheumatology, University of Florence, Florence, Italy
– sequence: 8
  givenname: László
  surname: Czirják
  fullname: Czirják, László
  email: duska.dragun@charite.de
  organization: Department of Rheumatology and Immunology, University of Pecs, Pecs, Hungary
– sequence: 9
  givenname: Ivo
  surname: Lukitsch
  fullname: Lukitsch, Ivo
  email: duska.dragun@charite.de
  organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany
– sequence: 10
  givenname: Mike
  surname: Becker
  fullname: Becker, Mike
  email: duska.dragun@charite.de
  organization: Department of Rheumatology, German Rheumatology Research Center, Leibniz Institute, Berlin, Germany
– sequence: 11
  givenname: Angela
  surname: Kill
  fullname: Kill, Angela
  email: duska.dragun@charite.de
  organization: Department of Rheumatology, German Rheumatology Research Center, Leibniz Institute, Berlin, Germany
– sequence: 12
  givenname: Jacob M
  surname: van Laar
  fullname: van Laar, Jacob M
  email: duska.dragun@charite.de
  organization: Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
– sequence: 13
  givenname: Rusan
  surname: Catar
  fullname: Catar, Rusan
  email: duska.dragun@charite.de
  organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany
– sequence: 14
  givenname: Friedrich C
  surname: Luft
  fullname: Luft, Friedrich C
  email: duska.dragun@charite.de
  organization: Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine, Berlin, Germany
– sequence: 15
  givenname: Gerd R
  surname: Burmester
  fullname: Burmester, Gerd R
  email: duska.dragun@charite.de
  organization: Department of Rheumatology, German Rheumatology Research Center, Leibniz Institute, Berlin, Germany
– sequence: 16
  givenname: Björn
  surname: Hegner
  fullname: Hegner, Björn
  email: duska.dragun@charite.de
  organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany
– sequence: 17
  givenname: Duska
  surname: Dragun
  fullname: Dragun, Duska
  email: duska.dragun@charite.de
  organization: Center for Cardiovascular Research, Charité University Hospital, Berlin, Germany
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23877242$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21081526$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1rFTEUhoNU7G117U4GRArCtPmYfMyyXD9aKbpQC3YTkkxGcp1Jrknm0v57M8ytQkG6yjnwvIfwPkfgwAdvAXiJ4ClChJ2p2J1iOG-Eco6fgBVqmKgxZPAArCCEpG5axg_BUUqbskKBxDNwiFEZKGYr8OPS78Kws6P1uQp91U_eZBe8Gio15aB8djp0zqZK_VTOp1ztVDLToGIVrbHbHGKqnK_SXcp2dKZKZrAxJJeeg6e9GpJ9sX-PwfcP77-tL-qrLx8v1-dXtaaY5hphrqxuGyqINhozziDSxHDYUMqEQqjTuuWm6RSmxlKqVS-0sBppxKglmByDk-XuNobfk01Zji4ZOwzK2zAl2UKOaMPbx0nRtA1uIYaFfP2A3IQpllKSRJxzwSDhvFCv9tSkR9vJbXSjinfyvt0CvNkDpTM19FF549I_jojirJk_RhfOlOZStL00LqtZQ47KDRJBOduWxbacbcvFdsmdPcjdn_5_ol4Srui6_Yur-EsyTjiVn6_X8hrd3Lwjn77Ki8K_XXg9bh49_getwMfw
CODEN ARDIAO
CitedBy_id crossref_primary_10_1097_TP_0b013e318234b337
crossref_primary_10_3389_fimmu_2024_1491324
crossref_primary_10_1016_j_atherosclerosissup_2012_10_034
crossref_primary_10_3390_biomedicines10020502
crossref_primary_10_1136_annrheumdis_2011_200195
crossref_primary_10_1007_s11926_015_0505_4
crossref_primary_10_1038_s41573_025_01158_9
crossref_primary_10_3389_fimmu_2021_684142
crossref_primary_10_1002_jmv_28864
crossref_primary_10_1111_bph_14213
crossref_primary_10_3389_fimmu_2021_677970
crossref_primary_10_1378_chest_12_2396
crossref_primary_10_1136_postgradmedj_2011_130364
crossref_primary_10_1186_ar4457
crossref_primary_10_1136_annrheumdis_2019_215341
crossref_primary_10_1016_j_atherosclerosis_2023_06_970
crossref_primary_10_1038_s41467_018_07598_9
crossref_primary_10_1111_aji_12072
crossref_primary_10_12688_f1000research_10022_1
crossref_primary_10_1093_abbs_gmr096
crossref_primary_10_1007_s00393_011_0914_3
crossref_primary_10_23736_S0393_3660_23_05188_4
crossref_primary_10_1016_j_autrev_2017_07_019
crossref_primary_10_3389_fimmu_2020_564526
crossref_primary_10_1016_j_rdc_2015_04_002
crossref_primary_10_1111_ajt_15571
crossref_primary_10_1161_HYPERTENSIONAHA_111_171348
crossref_primary_10_1016_j_semarthrit_2021_01_001
crossref_primary_10_1016_j_autrev_2022_103230
crossref_primary_10_1016_j_xkme_2023_100753
crossref_primary_10_1097_BOR_0b013e3283524b9a
crossref_primary_10_1016_j_autrev_2022_103231
crossref_primary_10_3899_jrheum_150061
crossref_primary_10_1136_ard_2023_224092
crossref_primary_10_1097_TP_0000000000001231
crossref_primary_10_1016_j_kint_2019_01_030
crossref_primary_10_1016_j_autrev_2019_102371
crossref_primary_10_1111_1756_185X_13001
crossref_primary_10_1186_ar4230
crossref_primary_10_3390_ijms23020927
crossref_primary_10_1007_s11926_012_0296_9
crossref_primary_10_1097_TP_0000000000001904
crossref_primary_10_1007_s00467_021_04969_1
crossref_primary_10_4049_jimmunol_1502190
crossref_primary_10_1016_j_autrev_2023_103386
crossref_primary_10_1016_j_transproceed_2021_01_013
crossref_primary_10_1136_rmdopen_2023_003626
crossref_primary_10_1371_journal_pone_0210023
crossref_primary_10_1016_j_clindermatol_2018_04_008
crossref_primary_10_1111_aji_12097
crossref_primary_10_1097_BOR_0000000000000959
crossref_primary_10_3389_fimmu_2018_00428
crossref_primary_10_3390_ijms24086960
crossref_primary_10_1038_srep23508
crossref_primary_10_1093_rheumatology_keaa747
crossref_primary_10_1016_j_explore_2013_10_001
crossref_primary_10_1186_s13075_022_02896_6
crossref_primary_10_1007_s10067_016_3504_6
crossref_primary_10_1007_s00281_015_0513_5
crossref_primary_10_1097_TP_0000000000003797
crossref_primary_10_1136_rmdopen_2024_004290
crossref_primary_10_1007_s40618_024_02412_4
crossref_primary_10_3389_fendo_2022_880002
crossref_primary_10_1186_s13075_018_1545_8
crossref_primary_10_1111_tri_13009
crossref_primary_10_1080_08916934_2021_1916915
crossref_primary_10_3899_jrheum_150474
crossref_primary_10_1007_s00393_024_01539_2
crossref_primary_10_1007_s00018_014_1713_1
crossref_primary_10_1016_j_autrev_2018_08_003
crossref_primary_10_1111_ajt_14053
crossref_primary_10_1093_rheumatology_keac594
crossref_primary_10_1093_rheumatology_ker414
crossref_primary_10_1097_TP_0000000000000179
crossref_primary_10_1136_annrheumdis_2020_217166
crossref_primary_10_3390_jpm11111207
crossref_primary_10_2169_internalmedicine_1423_18
crossref_primary_10_1016_j_clim_2025_110454
crossref_primary_10_1007_s00108_019_00699_7
crossref_primary_10_1038_nrrheum_2010_218
crossref_primary_10_1161_HYPERTENSIONAHA_119_12105
crossref_primary_10_1371_journal_pone_0100035
crossref_primary_10_1016_j_kint_2016_03_019
crossref_primary_10_1371_journal_pone_0129910
crossref_primary_10_1124_jpet_114_221606
crossref_primary_10_1586_edm_13_8
crossref_primary_10_3390_ijms23010244
crossref_primary_10_1016_j_freeradbiomed_2018_05_085
crossref_primary_10_2174_011573398X268623231212180622
crossref_primary_10_2174_0929867325666180201095743
crossref_primary_10_1093_ajh_hpu142
crossref_primary_10_1111_ajt_13866
crossref_primary_10_1097_TP_0000000000000182
crossref_primary_10_6064_2012_215308
crossref_primary_10_47184_ti_2021_01_04
crossref_primary_10_1164_rccm_201105_0927OC
crossref_primary_10_1016_j_transproceed_2018_05_022
crossref_primary_10_31083_j_fbs1504016
crossref_primary_10_1016_j_jcf_2014_07_007
crossref_primary_10_1161_JAHA_115_002323
crossref_primary_10_1002_art_39212
crossref_primary_10_1016_j_autrev_2015_10_005
crossref_primary_10_1586_ers_11_18
crossref_primary_10_1186_1750_1326_9_49
crossref_primary_10_3390_ijms25042299
crossref_primary_10_1111_tri_12282
crossref_primary_10_1177_23971983231168193
crossref_primary_10_1093_rheumatology_keu463
crossref_primary_10_1016_j_jaut_2021_102683
crossref_primary_10_3389_fimmu_2017_00075
crossref_primary_10_3390_medicina60010170
crossref_primary_10_5301_jsrd_5000249
crossref_primary_10_3109_10641955_2015_1051227
crossref_primary_10_1007_s40674_016_0050_y
crossref_primary_10_5301_jsrd_5000241
crossref_primary_10_3390_ijms222111793
crossref_primary_10_1177_2397198319870667
crossref_primary_10_3389_fimmu_2017_00603
crossref_primary_10_1097_TP_0000000000001853
crossref_primary_10_1080_1744666X_2019_1614915
crossref_primary_10_1016_j_humimm_2019_04_007
crossref_primary_10_1016_j_humimm_2019_04_008
crossref_primary_10_1016_j_ekir_2020_09_004
crossref_primary_10_1007_s00281_014_0425_9
crossref_primary_10_1016_j_trre_2017_08_005
crossref_primary_10_1586_eci_11_56
crossref_primary_10_1016_j_trre_2016_06_001
crossref_primary_10_1097_01_TP_0000436927_08026_a8
crossref_primary_10_1097_MOT_0b013e328355f12b
crossref_primary_10_1016_j_jri_2022_103777
crossref_primary_10_1016_j_kint_2021_04_044
crossref_primary_10_1124_pr_114_010454
crossref_primary_10_3390_diagnostics11050911
crossref_primary_10_1093_rheumatology_keac549
crossref_primary_10_1183_13993003_01949_2023
crossref_primary_10_1038_s41467_022_28905_5
crossref_primary_10_1111_bjd_17886
crossref_primary_10_3390_ijms21041382
crossref_primary_10_1097_BOR_0000000000000215
crossref_primary_10_1002_art_43099
crossref_primary_10_1016_j_imlet_2017_10_007
crossref_primary_10_1016_j_autrev_2014_12_001
crossref_primary_10_1016_j_jaad_2022_06_1199
crossref_primary_10_1016_j_autrev_2023_103310
crossref_primary_10_1038_nrrheum_2013_46
crossref_primary_10_1177_1759720X221109404
crossref_primary_10_1097_FJC_0000000000001264
crossref_primary_10_1097_MOT_0b013e3283636e55
crossref_primary_10_3390_jcm9092687
crossref_primary_10_1007_s00109_014_1190_x
crossref_primary_10_3389_fimmu_2018_02457
crossref_primary_10_1111_tri_12371
crossref_primary_10_1186_s40729_021_00398_9
crossref_primary_10_1007_s12016_022_08945_x
crossref_primary_10_1055_a_1120_8647
crossref_primary_10_1016_j_berh_2012_01_011
crossref_primary_10_1093_icvts_ivv344
crossref_primary_10_1007_s11936_021_00947_w
crossref_primary_10_1002_art_37873
crossref_primary_10_1016_j_humimm_2019_04_012
crossref_primary_10_3389_fimmu_2023_1213804
crossref_primary_10_1038_s41584_019_0322_7
crossref_primary_10_1161_JAHA_123_032441
crossref_primary_10_1080_09273948_2024_2308030
crossref_primary_10_1016_j_jacc_2019_02_067
crossref_primary_10_1016_j_jacc_2019_02_064
crossref_primary_10_3390_jcm13247752
crossref_primary_10_3389_fimmu_2022_895501
crossref_primary_10_3389_fimmu_2022_954007
crossref_primary_10_1007_s40674_021_00171_4
crossref_primary_10_1016_j_rdc_2022_08_002
crossref_primary_10_1186_ar4503
crossref_primary_10_1016_j_molimm_2020_12_027
crossref_primary_10_1586_1744666X_2016_1115717
crossref_primary_10_3390_biomedicines10092150
crossref_primary_10_1002_art_39865
crossref_primary_10_1111_ajt_12397
crossref_primary_10_1056_NEJMc1207233
crossref_primary_10_1016_j_niox_2019_02_006
crossref_primary_10_3109_07853890_2011_653396
crossref_primary_10_1136_annrheumdis_2021_222088
crossref_primary_10_3390_ijms24044178
crossref_primary_10_1016_j_humimm_2012_07_010
crossref_primary_10_1177_23971983231175213
crossref_primary_10_1016_j_tips_2020_11_013
crossref_primary_10_21693_1933_088X_16_2_61
crossref_primary_10_1002_jcp_31266
crossref_primary_10_1186_s12920_019_0632_2
crossref_primary_10_1016_j_autrev_2018_06_009
crossref_primary_10_1016_j_autrev_2012_05_011
crossref_primary_10_1097_MAJ_0b013e3182a55d24
crossref_primary_10_1111_exd_14159
crossref_primary_10_1164_rccm_201403_0442OC
crossref_primary_10_1007_s10067_019_04745_5
crossref_primary_10_3390_biom14091054
crossref_primary_10_5664_jcsm_8036
crossref_primary_10_1016_j_revmed_2016_02_016
crossref_primary_10_1164_rccm_201412_2322LE
crossref_primary_10_1038_nrrheum_2014_195
crossref_primary_10_3390_jcm11030833
crossref_primary_10_2147_CCID_S409490
crossref_primary_10_2217_ijr_13_65
crossref_primary_10_1038_nrrheum_2017_134
crossref_primary_10_1515_JLM_2011_051
crossref_primary_10_1016_j_autrev_2016_03_005
crossref_primary_10_1097_BOR_0000000000001035
crossref_primary_10_1161_CIRCRESAHA_113_300752
crossref_primary_10_3389_fimmu_2021_786039
crossref_primary_10_1016_j_jid_2017_03_032
crossref_primary_10_1155_ijr_1682081
crossref_primary_10_3389_fimmu_2022_1045523
crossref_primary_10_1152_physiol_00014_2013
crossref_primary_10_1053_j_ajkd_2015_03_033
crossref_primary_10_1055_a_2322_2289
crossref_primary_10_1097_TP_0b013e3182692ad2
crossref_primary_10_3389_fmed_2015_00013
crossref_primary_10_3389_fimmu_2022_925741
crossref_primary_10_1016_j_semarthrit_2022_152136
crossref_primary_10_3390_ijms23073984
crossref_primary_10_1007_s00281_015_0506_4
crossref_primary_10_3390_antib12010003
crossref_primary_10_1016_j_lpm_2014_06_007
crossref_primary_10_1111_micc_12440
crossref_primary_10_1007_s00296_016_3639_4
crossref_primary_10_1016_j_autrev_2024_103514
crossref_primary_10_1183_20734735_0183_2023
Cites_doi 10.1172/JCI31139
10.1136/ard.2005.048967
10.4065/70.11.1068
10.1126/science.1165480
10.1016/S0889-857X(05)70295-7
10.1136/ard.61.6.554
10.1002/art.24381
10.1136/ard.2007.079921
10.1136/ard.2006.066068
10.1016/S0031-6997(24)01458-3
10.1002/art.20676
10.1002/art.1780310302
10.1172/JCI26031
10.1002/1529-0131(200107)44:7<1484::AID-ART269>3.0.CO;2-Q
10.1002/art.11073
10.1161/HYPERTENSIONAHA.107.091322
10.1073/pnas.1834556100
10.1136/ard.2006.062901
10.1002/art.24365
10.7326/0003-4819-107-2-216
10.1172/JCI4106
10.1056/NEJMoa052955
10.1056/NEJMoa035717
10.1210/en.2003-0673
10.1002/art.11364
10.1146/annurev.pharmtox.47.120505.105134
10.1002/art.24364
10.1002/art.11113
ContentType Journal Article
Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
2015 INIST-CNRS
Copyright: 2011 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Copyright_xml – notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
– notice: 2015 INIST-CNRS
– notice: Copyright: 2011 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
88I
8AF
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9-
K9.
LK8
M0R
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
7T5
H94
DOI 10.1136/ard.2010.135772
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection (ProQuest)
Proquest Central Journals
Natural Science Collection (ProQuest)
BMJ Journals
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Proquest SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
Immunology Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
DatabaseTitleList MEDLINE
MEDLINE - Academic


AIDS and Cancer Research Abstracts
ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: Proquest Central Journals
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2060
EndPage 536
ExternalDocumentID 4008500991
21081526
23877242
10_1136_ard_2010_135772
ark_67375_NVC_V1ZZD3JS_H
annrheumdis
Genre Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article
GroupedDBID ---
.55
.GJ
.VT
169
23M
2WC
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8AF
8FE
8FH
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAXUO
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACOAB
ACOFX
ACPRK
ACQSR
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BKNYI
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
F5P
FDB
FYUFA
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
K9-
KQ8
L7B
LK8
M0R
M1P
M2P
M7P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
RWL
RXW
TAE
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W2D
W8F
WH7
WOQ
X6Y
X7M
YFH
YOC
YQY
ZGI
ZXP
0R~
3V.
BSCLL
FRP
IGG
RHF
AAFWJ
AALRI
AAYXX
CITATION
PHGZM
IQODW
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
PKN
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
7T5
H94
ID FETCH-LOGICAL-b525t-127aeb94583bcb267601b3c7045568a11dbb97c4da25ce55baf8b8eb1b165e323
IEDL.DBID 7X7
ISSN 0003-4967
1468-2060
IngestDate Fri Jul 11 12:27:31 EDT 2025
Tue Aug 05 10:39:59 EDT 2025
Fri Jul 25 11:17:46 EDT 2025
Sat Feb 15 01:21:14 EST 2025
Mon Jul 21 09:18:22 EDT 2025
Thu Apr 24 22:52:56 EDT 2025
Tue Jul 01 04:23:20 EDT 2025
Wed Oct 30 10:01:21 EDT 2024
Thu Apr 24 23:06:54 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Autoimmunity
Immunopathology
Connective tissue disease
Skin disease
Blood vessel
Systemic disease
Rheumatology
Autoantibody
Autoimmune disease
Scleroderma
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b525t-127aeb94583bcb267601b3c7045568a11dbb97c4da25ce55baf8b8eb1b165e323
Notes ark:/67375/NVC-V1ZZD3JS-H
href:annrheumdis-70-530.pdf
ArticleID:annrheumdis135772
PMID:21081526
local:annrheumdis;70/3/530
EUSTAR investigators
istex:EB5D4917B5AA995DD0932E5FB9F057BE8ECEB24D
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 21081526
PQID 1777860377
PQPubID 2041045
PageCount 7
ParticipantIDs proquest_miscellaneous_907154792
proquest_miscellaneous_849429020
proquest_journals_1777860377
pubmed_primary_21081526
pascalfrancis_primary_23877242
crossref_citationtrail_10_1136_ard_2010_135772
crossref_primary_10_1136_ard_2010_135772
istex_primary_ark_67375_NVC_V1ZZD3JS_H
bmj_primary_10_1136_ard_2010_135772
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2011-03-01
PublicationDateYYYYMMDD 2011-03-01
PublicationDate_xml – month: 03
  year: 2011
  text: 2011-03-01
  day: 01
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
– name: Kidlington
PublicationTitle Annals of the rheumatic diseases
PublicationTitleAlternate Ann Rheum Dis
PublicationYear 2011
Publisher BMJ Publishing Group Ltd and European League Against Rheumatism
BMJ Publishing Group
Elsevier Limited
Publisher_xml – name: BMJ Publishing Group Ltd and European League Against Rheumatism
– name: BMJ Publishing Group
– name: Elsevier Limited
References Rich, Dantzker, Ayres 1987; 107
Schneider, Boesen, Pollock 2007; 47
Davies, Ando, Lin 2005; 115
Steen, Medsger 2007; 66
Wallukat, Homuth, Fischer 1999; 103
Denton, Humbert, Rubin 2006; 65
Peterson, Nelson, Su 1995; 70
Bostrom, Yu, Kan 2009; 323
LeRoy, Medsger 1992; 10
Korn, Mayes, Matucci Cerinic 2004; 50
Vitali, Bombardieri, Jonsson 2002; 61
LeRoy 1996; 22
Mayes, Lacey, Beebe-Dimmer 2003; 48
Xia, Ramin, Kellems 2007; 50
de Gasparo, Catt, Inagami 2000; 52
Min, Cui, Yahata 2004; 145
Kawaguchi, Takagi, Hara 2004; 50
Denton, Pope, Peter 2008; 67
Malcarne, Hansdottir, McKinney 2007; 34
Reveille, Solomon 2003; 49
Arnett, Edworthy, Bloch 1988; 31
Baroni, Santillo, Bevilacqua 2006; 354
Varga, Abraham 2007; 117
Walker, Tyndall, Czirják 2007; 66
Dragun, Müller, Bräsen 2005; 352
Praprotnik, Blank, Meroni 2001; 44
LeRoy, Black, Fleischmajer 1988; 15
Classen, Henrohn, Rorsman 2009; 60
Yamane, Miyauchi, Suzuki 1992; 19
Dragun, Distler, Riemekasten 2009; 60
Wei, Ahn, Shenoy 2003; 100
Loizos, Lariccia, Weiner 2009; 60
Mayes (10.1136/ard.2010.135772_bib2) 2003; 48
LeRoy (10.1136/ard.2010.135772_bib20) 1992; 10
Wallukat (10.1136/ard.2010.135772_bib14) 1999; 103
Denton (10.1136/ard.2010.135772_bib5) 2008; 67
Bostrom (10.1136/ard.2010.135772_bib27) 2009; 323
Malcarne (10.1136/ard.2010.135772_bib4) 2007; 34
Schneider (10.1136/ard.2010.135772_bib12) 2007; 47
Xia (10.1136/ard.2010.135772_bib15) 2007; 50
Korn (10.1136/ard.2010.135772_bib8) 2004; 50
Classen (10.1136/ard.2010.135772_bib24) 2009; 60
Kawaguchi (10.1136/ard.2010.135772_bib9) 2004; 50
Rich (10.1136/ard.2010.135772_bib21) 1987; 107
Reveille (10.1136/ard.2010.135772_bib29) 2003; 49
Min (10.1136/ard.2010.135772_bib32) 2004; 145
LeRoy (10.1136/ard.2010.135772_bib16) 1988; 15
Walker (10.1136/ard.2010.135772_bib17) 2007; 66
Vitali (10.1136/ard.2010.135772_bib22) 2002; 61
Dragun (10.1136/ard.2010.135772_bib13) 2005; 352
LeRoy (10.1136/ard.2010.135772_bib3) 1996; 22
Steen (10.1136/ard.2010.135772_bib6) 2007; 66
Praprotnik (10.1136/ard.2010.135772_bib28) 2001; 44
Davies (10.1136/ard.2010.135772_bib31) 2005; 115
Denton (10.1136/ard.2010.135772_bib7) 2006; 65
Loizos (10.1136/ard.2010.135772_bib25) 2009; 60
Peterson (10.1136/ard.2010.135772_bib19) 1995; 70
Yamane (10.1136/ard.2010.135772_bib10) 1992; 19
Dragun (10.1136/ard.2010.135772_bib26) 2009; 60
Baroni (10.1136/ard.2010.135772_bib23) 2006; 354
Arnett (10.1136/ard.2010.135772_bib18) 1988; 31
Varga (10.1136/ard.2010.135772_bib1) 2007; 117
de Gasparo (10.1136/ard.2010.135772_bib11) 2000; 52
Wei (10.1136/ard.2010.135772_bib30) 2003; 100
21374902 - Nat Rev Rheumatol. 2011 Feb;7(2):71. doi: 10.1038/nrrheum.2010.218.
References_xml – volume: 50
  start-page: 3985
  year: 2004
  article-title: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist
  publication-title: Arthritis Rheum
– volume: 354
  start-page: 2667
  year: 2006
  article-title: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis
  publication-title: N Engl J Med
– volume: 50
  start-page: 269
  year: 2007
  article-title: Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia
  publication-title: Hypertension
– volume: 115
  start-page: 1972
  year: 2005
  article-title: Thyrotropin receptor-associated diseases: from adenomata to Graves disease
  publication-title: J Clin Invest
– volume: 70
  start-page: 1068
  year: 1995
  article-title: Classification of morphea (localized scleroderma)
  publication-title: Mayo Clin Proc
– volume: 61
  start-page: 554
  year: 2002
  article-title: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group
  publication-title: Ann Rheum Dis
– volume: 60
  start-page: 907
  year: 2009
  article-title: Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology
  publication-title: Arthritis Rheum
– volume: 10
  start-page: 485
  year: 1992
  article-title: Raynaud's phenomenon: a proposal for classification
  publication-title: Clin Exp Rheumatol
– volume: 65
  start-page: 1336
  year: 2006
  article-title: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions
  publication-title: Ann Rheum Dis
– volume: 60
  start-page: 1137
  year: 2009
  article-title: Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis
  publication-title: Arthritis Rheum
– volume: 66
  start-page: 940
  year: 2007
  article-title: Changes in causes of death in systemic sclerosis, 1972–2002
  publication-title: Ann Rheum Dis
– volume: 52
  start-page: 415
  year: 2000
  article-title: International union of pharmacology. XXIII. The angiotensin II receptors
  publication-title: Pharmacol Rev
– volume: 15
  start-page: 202
  year: 1988
  article-title: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
  publication-title: J Rheumatol
– volume: 50
  start-page: 216
  year: 2004
  article-title: Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors
  publication-title: Arthritis Rheum
– volume: 48
  start-page: 2246
  year: 2003
  article-title: Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population
  publication-title: Arthritis Rheum
– volume: 19
  start-page: 1566
  year: 1992
  article-title: Significance of plasma endothelin-1 levels in patients with systemic sclerosis
  publication-title: J Rheumatol
– volume: 107
  start-page: 216
  year: 1987
  article-title: Primary pulmonary hypertension. A national prospective study
  publication-title: Ann Intern Med
– volume: 323
  start-page: 1610
  year: 2009
  article-title: Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site
  publication-title: Science
– volume: 100
  start-page: 10782
  year: 2003
  article-title: Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2
  publication-title: Proc Natl Acad Sci USA
– volume: 352
  start-page: 558
  year: 2005
  article-title: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection
  publication-title: N Engl J Med
– volume: 103
  start-page: 945
  year: 1999
  article-title: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor
  publication-title: J Clin Invest
– volume: 44
  start-page: 1484
  year: 2001
  article-title: Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications
  publication-title: Arthritis Rheum
– volume: 145
  start-page: 253
  year: 2004
  article-title: Regulation of collagen synthesis in mouse skin fibroblasts by distinct angiotensin II receptor subtypes
  publication-title: Endocrinology
– volume: 31
  start-page: 315
  year: 1988
  article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
  publication-title: Arthritis Rheum
– volume: 117
  start-page: 557
  year: 2007
  article-title: Systemic sclerosis: a prototypic multisystem fibrotic disorder
  publication-title: J Clin Invest
– volume: 34
  start-page: 359
  year: 2007
  article-title: Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis
  publication-title: J Rheumatol
– volume: 47
  start-page: 731
  year: 2007
  article-title: Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease
  publication-title: Annu Rev Pharmacol Toxicol
– volume: 67
  start-page: 1222
  year: 2008
  article-title: Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases
  publication-title: Ann Rheum Dis
– volume: 22
  start-page: 675
  year: 1996
  article-title: Systemic sclerosis. A vascular perspective
  publication-title: Rheum Dis Clin North Am
– volume: 66
  start-page: 754
  year: 2007
  article-title: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database
  publication-title: Ann Rheum Dis
– volume: 49
  start-page: 399
  year: 2003
  article-title: Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies
  publication-title: Arthritis Rheum
– volume: 60
  start-page: 1145
  year: 2009
  article-title: Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera
  publication-title: Arthritis Rheum
– volume: 117
  start-page: 557
  year: 2007
  ident: 10.1136/ard.2010.135772_bib1
  article-title: Systemic sclerosis: a prototypic multisystem fibrotic disorder
  publication-title: J Clin Invest
  doi: 10.1172/JCI31139
– volume: 65
  start-page: 1336
  year: 2006
  ident: 10.1136/ard.2010.135772_bib7
  article-title: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2005.048967
– volume: 10
  start-page: 485
  year: 1992
  ident: 10.1136/ard.2010.135772_bib20
  article-title: Raynaud's phenomenon: a proposal for classification
  publication-title: Clin Exp Rheumatol
– volume: 70
  start-page: 1068
  year: 1995
  ident: 10.1136/ard.2010.135772_bib19
  article-title: Classification of morphea (localized scleroderma)
  publication-title: Mayo Clin Proc
  doi: 10.4065/70.11.1068
– volume: 323
  start-page: 1610
  year: 2009
  ident: 10.1136/ard.2010.135772_bib27
  article-title: Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site
  publication-title: Science
  doi: 10.1126/science.1165480
– volume: 22
  start-page: 675
  year: 1996
  ident: 10.1136/ard.2010.135772_bib3
  article-title: Systemic sclerosis. A vascular perspective
  publication-title: Rheum Dis Clin North Am
  doi: 10.1016/S0889-857X(05)70295-7
– volume: 61
  start-page: 554
  year: 2002
  ident: 10.1136/ard.2010.135772_bib22
  article-title: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.61.6.554
– volume: 60
  start-page: 1137
  year: 2009
  ident: 10.1136/ard.2010.135772_bib24
  article-title: Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.24381
– volume: 67
  start-page: 1222
  year: 2008
  ident: 10.1136/ard.2010.135772_bib5
  article-title: Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2007.079921
– volume: 66
  start-page: 940
  year: 2007
  ident: 10.1136/ard.2010.135772_bib6
  article-title: Changes in causes of death in systemic sclerosis, 1972–2002
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2006.066068
– volume: 52
  start-page: 415
  year: 2000
  ident: 10.1136/ard.2010.135772_bib11
  article-title: International union of pharmacology. XXIII. The angiotensin II receptors
  publication-title: Pharmacol Rev
  doi: 10.1016/S0031-6997(24)01458-3
– volume: 50
  start-page: 3985
  year: 2004
  ident: 10.1136/ard.2010.135772_bib8
  article-title: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist
  publication-title: Arthritis Rheum
  doi: 10.1002/art.20676
– volume: 34
  start-page: 359
  year: 2007
  ident: 10.1136/ard.2010.135772_bib4
  article-title: Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis
  publication-title: J Rheumatol
– volume: 31
  start-page: 315
  year: 1988
  ident: 10.1136/ard.2010.135772_bib18
  article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.1780310302
– volume: 115
  start-page: 1972
  year: 2005
  ident: 10.1136/ard.2010.135772_bib31
  article-title: Thyrotropin receptor-associated diseases: from adenomata to Graves disease
  publication-title: J Clin Invest
  doi: 10.1172/JCI26031
– volume: 44
  start-page: 1484
  year: 2001
  ident: 10.1136/ard.2010.135772_bib28
  article-title: Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications
  publication-title: Arthritis Rheum
  doi: 10.1002/1529-0131(200107)44:7<1484::AID-ART269>3.0.CO;2-Q
– volume: 48
  start-page: 2246
  year: 2003
  ident: 10.1136/ard.2010.135772_bib2
  article-title: Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population
  publication-title: Arthritis Rheum
  doi: 10.1002/art.11073
– volume: 15
  start-page: 202
  year: 1988
  ident: 10.1136/ard.2010.135772_bib16
  article-title: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
  publication-title: J Rheumatol
– volume: 50
  start-page: 269
  year: 2007
  ident: 10.1136/ard.2010.135772_bib15
  article-title: Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.107.091322
– volume: 100
  start-page: 10782
  year: 2003
  ident: 10.1136/ard.2010.135772_bib30
  article-title: Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1834556100
– volume: 66
  start-page: 754
  year: 2007
  ident: 10.1136/ard.2010.135772_bib17
  article-title: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2006.062901
– volume: 60
  start-page: 1145
  year: 2009
  ident: 10.1136/ard.2010.135772_bib25
  article-title: Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera
  publication-title: Arthritis Rheum
  doi: 10.1002/art.24365
– volume: 107
  start-page: 216
  year: 1987
  ident: 10.1136/ard.2010.135772_bib21
  article-title: Primary pulmonary hypertension. A national prospective study
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-107-2-216
– volume: 103
  start-page: 945
  year: 1999
  ident: 10.1136/ard.2010.135772_bib14
  article-title: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor
  publication-title: J Clin Invest
  doi: 10.1172/JCI4106
– volume: 354
  start-page: 2667
  year: 2006
  ident: 10.1136/ard.2010.135772_bib23
  article-title: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa052955
– volume: 352
  start-page: 558
  year: 2005
  ident: 10.1136/ard.2010.135772_bib13
  article-title: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa035717
– volume: 145
  start-page: 253
  year: 2004
  ident: 10.1136/ard.2010.135772_bib32
  article-title: Regulation of collagen synthesis in mouse skin fibroblasts by distinct angiotensin II receptor subtypes
  publication-title: Endocrinology
  doi: 10.1210/en.2003-0673
– volume: 50
  start-page: 216
  year: 2004
  ident: 10.1136/ard.2010.135772_bib9
  article-title: Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors
  publication-title: Arthritis Rheum
  doi: 10.1002/art.11364
– volume: 47
  start-page: 731
  year: 2007
  ident: 10.1136/ard.2010.135772_bib12
  article-title: Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease
  publication-title: Annu Rev Pharmacol Toxicol
  doi: 10.1146/annurev.pharmtox.47.120505.105134
– volume: 60
  start-page: 907
  year: 2009
  ident: 10.1136/ard.2010.135772_bib26
  article-title: Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology
  publication-title: Arthritis Rheum
  doi: 10.1002/art.24364
– volume: 19
  start-page: 1566
  year: 1992
  ident: 10.1136/ard.2010.135772_bib10
  article-title: Significance of plasma endothelin-1 levels in patients with systemic sclerosis
  publication-title: J Rheumatol
– volume: 49
  start-page: 399
  year: 2003
  ident: 10.1136/ard.2010.135772_bib29
  article-title: Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies
  publication-title: Arthritis Rheum
  doi: 10.1002/art.11113
– reference: 21374902 - Nat Rev Rheumatol. 2011 Feb;7(2):71. doi: 10.1038/nrrheum.2010.218.
SSID ssj0000818
Score 2.4826446
Snippet Background Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated...
Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated in...
BACKGROUND: Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis. The renin-angiotensin and endothelin systems have been implicated...
SourceID proquest
pubmed
pascalfrancis
crossref
istex
bmj
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 530
SubjectTerms Adolescent
Adult
Antibody Specificity
Autoantibodies - blood
Autoantibodies - immunology
Biological and medical sciences
Biomarkers - blood
Diseases of the osteoarticular system
Endothelium, Vascular - immunology
Epidemiologic Methods
Experiments
Female
Gene expression
Humans
Immunoglobulins
Immunology
Kinases
Male
Medical sciences
Microcirculation - immunology
Middle Aged
Mortality
Patients
Prognosis
Proteins
Raynaud disease
Receptor, Angiotensin, Type 1 - immunology
Receptor, Endothelin A - immunology
Rheumatology
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Scleroderma
Scleroderma, Systemic - immunology
Studies
Thyroid gland
Young Adult
Title Involvement of functional autoantibodies against vascular receptors in systemic sclerosis
URI http://ard.bmj.com/content/70/3/530.full
https://api.istex.fr/ark:/67375/NVC-V1ZZD3JS-H/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/21081526
https://www.proquest.com/docview/1777860377
https://www.proquest.com/docview/849429020
https://www.proquest.com/docview/907154792
Volume 70
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELZoV0JcEO8ulJUlEOISGsev5ISgtFoqsUJAq6UXy04cFB7J0mQlfj4zcbKrHhbO8SP6xh5_9nyaIeR54vOYuYRFTjIeiVLEkS18GVkF5LzgnsFmR7XFQs3PxdlSLocHt3aQVY4-sXfURZPjG_kR05jpLOZav179jrBqFEZXhxIae2SCqctwVeul3nrilKVjxTyRKT2k9mFcHQH8QdfFuNSYHnjP_fp-7WyaIMx_UCtpW4CrDHUudhPR_kA6vUNuD0ySvgmmv0tu-PoeuflhiJXfJ1_f1-B6-nTgHW1KiidYePijdt01gGjlGtQQUvvNVsAS6ahKpeAF_QrL8NCqpiHXc5XTFqaB_67aB-T89OTL8TwaCimABRLZRSzR1rsMQ6Qud4lCHYzjuQY6J1VqGSucy3QuCpvI3EvpbJm6FLy4Y0p6nvCHZL9uan9AqIhT7QoglZIrwXySOQcNJFzaVOxLKafkGQBpViFVhumvGFwZgNsg3CbAPSWvRqBNPuQix5IYP3d3eLnp8N-xX_SW27SzVz9QvaalWVwcmwt2efmOn3028ymZXTPtpgOwGBhHwEiHo63NsLNbs12HU0I3n2FPYqDF1r5ZtyYVGRzzQMR3N8mA2kmhM5jkUVhF2-kZrFuZqMf_nv4JuRXet1EPd0j2u6u1fwoEqXOzfhfMyOTtyeLjp7-w9w1h
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKKwEXxJuFUizxEJe0sRPbyQEh1FLt9rEX2mrpxdiJg8IjWZpdAX-K38hMnOyqh4VTz-tHNDP-_Nn-doaQF9xlIbOcBVawKIiLOAxM7orASCDneeQYLHZUW4zl8DQ-mIjJGvnT_xcGZZU9JrZAndcZ3pHvMIWZzsJIqbfTHwFWjcLX1b6Ehg-LQ_f7JxzZmjejPfDvS87335_sDoOuqgB8DhezgHFlnE3xvdBmlksUhdgoU8BthEwMY7m1qcri3HCROSGsKRKbAKRZJoWLMNEBQP4GbLwhHvbURC2RP2FJX6EvTqXqUgmxSO6Au72OjEVCYTria_b7l0t74Qa69RdqM00D7il8XY3VxLfdAPdvk1sdc6XvfKjdIWuuukuuH3dv8_fIx1EFUNemH5_RuqC4Y_qLRmrmsxo8WNoaNYvUfDYlsFLaq2ApoK6bYtkfWlbU55YuM9rANPDdZXOfnF6JiR-Q9aqu3CNC4zBRNgcSKyIZM8dTa6GBgEOiDF0hxIA8B0PqqU_NodsjTSQ1mFujubU394Bs94bWWZf7HEtwfFvd4fWiw3_HftV6btHOXHxFtZwSeny2q8_Y-fledPBBDwdk65JrFx2ANcE4MYy02ftad0jS6GXcDwhd_AwYgA87pnL1vNFJnAKtAOK_ukkKVFLEKoVJHvooWk7PIG4Fl4__Pf0zcmN4cnykj0bjwyfkpr9bRy3eJlmfXczdUyBnM7vVrghKPl31EvwLEoVIng
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGK028IO50jGGJi3gJjZPYTh4QgnVVu0E1AZu2vRg7cVAGJGVJBfw1fh3n5NJqD4WnPdeX6Nz8HfvrOYQ89WzsMuMxx3DmO0EauI5ObOpoAeA88S0DZ0e2xUxMjoL9E36yQf50_4VBWmUXE-tAnRQx3pEPmcRKZ64v5TBtaRGHo_Hr-Q8HO0jhS2vXTqMxkQP7-yekb-Wr6Qh0_czzxnufdidO22EAPs3jlcM8qa2J8O3QxMYTSBAxfiwB53ARasYSYyIZB4n2eGw5NzoNTQjhzTDBrY9FDyD89yVmRT3Sf7s3O_ywOgdCFnb9-oJIyLawEPPFEJTfsMqYzyUWJ75mvp9fOhn7qORfyNTUJSgrbbpsrIfB9XE4vklutDiWvmkM7xbZsPltsvm-fam_Q06nOQS-uhh5RYuU4vnZXDtSvagK0GdmCmQwUv1FZ4BRaceJpRCD7RybANEsp02l6SymJWwD352Vd8nRlQj5HunlRW4fEBq4oTQJQFrui4BZLzIGBnBIGYVrU84H5AkIUs2bQh2qTnB8oUDcCsWtGnEPyMtO0CpuK6FjQ45v6ye8WE7479rPa80tx-mLr8idk1zNjnfVMTs7G_n7H9VkQHYuqXY5ATAUrBPAStudrlUbV0q18oIBocufISLgM4_ObbEoVRhEADIgDVg_JAJ75YGMYJP7jRWttmdgt9wTW__e_jHZBPdT76azg4fkenPRjsS8bdKrLhb2ESC1yuy0LkHJ56v2wr81RE45
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Involvement+of+functional+autoantibodies+against+vascular+receptors+in+systemic+sclerosis&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Riemekasten%2C+Gabriela&rft.au=Philippe%2C+Aur%C3%A9lie&rft.au=N%C3%A4ther%2C+Melanie&rft.au=Slowinski%2C+Torsten&rft.date=2011-03-01&rft.eissn=1468-2060&rft.volume=70&rft.issue=3&rft.spage=530&rft_id=info:doi/10.1136%2Fard.2010.135772&rft_id=info%3Apmid%2F21081526&rft.externalDocID=21081526
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon